Advertisement
Case Reports| Volume 326, ISSUE 2, P89-93, August 2003

Download started.

Ok

Hyponatremia Associated with 3,4-Methylenedioxymethylamphetamine (“Ecstasy”) Abuse

      ABSTRACT

      We present a case of acute, symptomatic hyponatremia in a young woman that developed after use of 3,4-methylenedioxymethylamphetamine (MDMA), more commonly known as “ecstasy.” The patient was treated with 5% saline and had complete recovery. The pathogenesis of MDMA-associated hyponatremia involves excessive water intake and inappropriately elevated antidiuretic hormone (ADH) levels. It seems that young, premenopausal women are at particularly high risk for the development of severe, symptomatic hyponatremia after use of this drug. Review of the literature revealed 4 fatal outcomes from MDMA-associated hyponatremia. All were women and all died from cerebellar tonsillar herniation. We suggest that acute hyponatremia that develops after MDMA use may be a life-threatening condition. Recent recommendation that MDMA users should drink large volumes of water may not be appropriate.

      KEY INDEXING TERMS

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vastag B.
        Ecstasy experts want realistic messages.
        JAMA. 2001; 286: 777
        • O’Connor B.
        Hazards associated with the recreational drug ‘ecstasy’.
        Br J Hosp Med. 1994; 52: 507-514
        • Burgess C.
        • O’Donohoe A.
        • Gill M.
        Agony and ecstasy: a review of MDMA effects and toxicity.
        Eur Psychiatry. 2000; 15: 287-294
        • Brown C.
        • Osterloh J.
        Multiple severe complications from recreational ingestion of MDMA (‘ecstasy’).
        JAMA. 1987; 258: 780-781
        • Maxwell D.L.
        • Polkey M.I.
        • Henry J.A.
        Hyponatraemia and catatonic stupor after taking “ecstasy”.
        BMJ. 1993; 307: 1399
        • Halterman R.K.
        • Berl T.
        Therapy of dysnatremic disorders.
        in: Brady H.R. Wilcox C.S. Therapy in nephrology and hypertension. WB Saunders Company, Philadelphia1999: 257-269
        • Furst H.
        • Hallows K.R.
        • Post J.
        The urine/plasma electrolyte ratio.
        Am J Med Sci. 2000; 319: 240-244
        • Holden R.
        • Jackson M.A.
        Near-fatal hyponatraemic coma due to vasopressin over-secretion after “ecstasy” (3,4-MDMA) [letter].
        Lancet. 1996; 347: 1052
        • Henry J.A.
        • Fallon J.K.
        • Kicman A.T.
        Low-dose MDMA (“ecstasy”) induces vasopressin secretion [letter].
        Lancet. 1998; 351: 1784
        • Cherney D.Z.I.
        • Davids M.R.
        • Halperin M.L.
        Acute hyponatremia and “ecstasy”: insights from a quantitative and integrative analysis.
        QJM. 2002; 95: 475-483
        • Maesaka J.K.
        • Gupta S.
        • Fishbane S.
        Cerebral salt-wasting syndrome: does it exist?.
        Nephron. 1999; 82: 100-109
        • Palmer B.F.
        Hyponatremia in neurosurgical patient: syndrome of inappropriate antidiuretic hormone secretion versus cerebral salt wasting.
        Nephrol Dial Transplant. 2000; 15: 262-268
        • Maesaka J.K.
        • Fishbane S.
        Regulation of renal urate excretion: a critical review.
        Am J Kidney Dis. 1998; 32: 917-933
        • Gomez-Balaguer M.
        • Pefia H.
        • Morillas C.
        Syndrome of inappropriate antidiuretic hormone secretion and “designer drugs” (Ecstasy).
        J Pediatr Endocrinol Metab. 2000; 13: 437-438
        • O’Connor A.
        • Cluroe A.
        • Couch R.
        Death from hyponatraemia-induced cerebral oedema associated with MDMA (“Ecstasy”) use.
        NZ Med J. 1999; 112: 255-256
        • Holmes S.B.
        • Banerjee A.K.
        • Alexander W.D.
        Hyponatraemia and seizures after ecstasy use.
        Postgrad Med J. 1999; 75: 32-33
        • Magee C.
        • Staunton H.
        • Tormey W.
        Hyponatraemia, seizures and stupor associated with ecstasy ingestion in a female.
        Ir Med J. 1998; 91: 178
        • Ajaelo I.
        • Koenig K.
        • Snoey E.
        Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use.
        Acad Emerg Med. 1998; 5: 839-840
        • Watson I.D.
        • Serlin M.
        • Moncur P.
        Acute hyponatraemia.
        Postgrad Med J. 1997; 73: 433-434
        • Nuvials X.
        • Masclans J.R.
        • Peracaula R.
        Hyponatraemic coma after ecstasy ingestion [letter].
        Intensive Care Med. 1997; 23: 480
        • Box S.A.
        • Prescott L.F.
        • Freestone S.
        Hyponatraemia at a rave.
        Postgrad Med J. 1997; 73: 53-54
        • Parr M.J.
        • Low H.M.
        • Botterill P.
        Hyponatraemia and death after “ecstasy” ingestion.
        Med J Aust. 1997; 166: 136-137
        • Matthai S.M.
        • Davidson D.C.
        • Sills J.A.
        Cerebral oedema after ingestion of MDMA (“ecstasy”) and unrestricted intake of water [letter].
        BMJ. 1996; 312: 1359
        • Satchell S.C.
        • Connaughton M.
        Inappropriate antidiuretic hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion.
        Br J Hosp Med. 1994; 51: 495
        • Kessel B.
        Hyponatraemia after ingestion of “ecstasy”[letter].
        BMJ. 1994; 308: 414
        • Balmelli C.
        • Kupferschmidt H.
        • Rentsch K.
        Fatal brain oedema after ingestion of ecstasy and benzylpiperazine.
        Dtsch Med Wschr. 2001; 126: 809-811
        • Traub S.J.
        • Hoffman R.S.
        • Nelson L.S.
        The “Ecstasy” hangover: hyponatremia due to 3,4-methylenedioxymethamphetamine.
        J Urban Health. 2002; 79: 549-555
        • Gore S.M.
        Fatal uncertainty: death-rate from use of ecstasy or heroin.
        Lancet. 1999; 354: 1265-1266
        • Mueller P.D.
        • Korey W.S.
        Death by “ecstasy”: the serotonin syndrome?.
        Ann Emerg Med. 1998; 32: 377-380
        • Milroy C.M.
        • Clark J.C.
        • Forrest A.R.W.
        Pathology of deaths associated with “ecstasy” and “eve” misuse.
        J Clin Pathol. 1996; 49: 149-153
        • Dowling P.
        • McDonough E.T.
        • Bost R.O.
        ‘Eve’ and ‘Ecstasy’. A report of five deaths associated with the use of MDEA and MDMA.
        JAMA. 1987; 257: 1615-1617
        • Henry J.A.
        • Jeffreys K.J.
        • Dawling S.
        Toxicity and deaths from 3,4 methylenedioxymethamphetamine (“ecstasy”).
        Lancet. 1992; 340: 384-387
        • Walubo A.
        • Seger D.
        Fatal multi-organ failure after suicidal overdose with MDMA, ‘Ecstasy’: case report and review of the literature.
        Hum Exp Toxicol. 1999; 18: 119-125
        • Arieff A.I.
        Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective sur-gery in healthy women.
        N Engl J Med. 1986; 314: 1529-1535
        • Fraser C.L.
        • Arieff A.I.
        Epidemiology, pathophysiology, and management of hyponatremic encephalopathy.
        Am J Med. 1997; 102: 67-77
        • Lauriat S.M.
        • Berl T.
        The hyponatremic patient: practi-cal focus on therapy.
        J Am Soc Nephrol. 1997; 8: 1599-1607
        • Hartung T.K.
        • Schofield E.
        • Short A.I.
        Hypo-natremic states following 3,4-methylenedioxymethamphet-amine (MDMA, “ecstasy”) ingestion.
        QJM. 2002; 95: 431-437